Psoriasis Therapeutic Pipeline Analysis

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: October 2017
Report Code: LS11042
Available Format:
Pages: 301

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Disease Overview

Psoriasis is a medical condition that includes chronic inflammation and scaling on the skin and develops when the skin cells rapidly grow below the surface of the skin and get deposited on the surface before they get mature. Usually this process takes about a month, but in psoriasis it may occur in a few days. Psoriasis leads to the development of thick patches of inflamed skin with a silvery scale covering. These patches are also referred to as plaques and they itch or feel sore. They mostly occur on knees, elbows, other parts of the legs, lower back, scalp, soles of the feet, face and palms. Psoriasis can also affect the toenails, the fingernails, inside the mouth and the soft tissues of the genitals. Pain and itching may interfere with basic functions such as self-care, sleep and walking. Psoriasis is caused when the T-cells accidently get involved and become active to the extent of triggering other immune responses, thus, resulting in inflammation and rapid turnover of skin cells.



Psoriasis Therapeutics Pipeline Analysis

Another major source of developing the disease is its presence in the family history of an individual. Psoriasis is diagnosed by examining a small skin sample from a patient, under a microscope. There are several forms of psoriasis including guttate psoriasis, plaque psoriasis, erythrodermic psoriasis, inverse psoriasis, pustular psoriasis and psoriatic arthritis. The treatment of psoriasis includes topical treatment, phototherapy and systemic therapy. Topical treatment includes application of ointment or cream forms of corticosteroids, vitamin D3, retinoids, coal tar, or anthralin. Phototherapy includes exposure of UV light in controlled conditions, while systemic treatment includes retinoids, cyclosporine, methotrexate, PDE4 inhibitors and biologic response modifiers medicines.

Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies by developing topical drugs that have lower risk of side effects, and safe administration. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.

Pipeline Analysis

As of August 2017, the psoriasis therapeutics pipeline comprises of approximately 150 drug candidates in different stages of development. 

Competitive Landscape

Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 4000
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 5000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 8000

Pre-Purchase Enquiry